Lanean...
ACTR-70. IMPACT OF BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND POOR PERFORMANCE STATUS
Clinical trials have showed that bevacizumab is beneficial for patients with recurrent glioblastoma and partially effective against newly diagnosed glioblastoma. However, glioblastoma patients with poor performance status (PS) were excluded from these clinical trials, and the efficacy of bevacizumab...
Gorde:
| Argitaratua izan da: | Neuro Oncol |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693094/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.057 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|